Search results for "Protective Agent"

showing 10 items of 226 documents

Increased Hypoxic Tolerance by Chemical Inhibition of Oxidative Phosphorylation: “Chemical Preconditioning”

1997

A short ischemic episode preceding sustained ischemia is known to increase tolerance against ischemic cell death. We report early-onset long-lasting neuroprotection against in vitro hypoxia by preceding selective chemical inhibition of oxidative phosphorylation: “chemical preconditioning.” The amplitude of CA1population spikes (psap) in hippocampal slices prepared from control animals (control slices) was 31 ± 27% (mean ± SD) upon 45-min recovery from 15-min in vitro hypoxia. In slices prepared from animals treated in vivo with 20 mg/kg 3-nitropropionate (3-np) 1–24 h prior to slice preparation (preconditioned slices), psap improved to 90 ± 15% (p < 0.01). Posthypoxic oxygen free radical…

MalePotassium ChannelsFree RadicalsPopulationIschemiaNerve Tissue ProteinsBiologyPharmacologyHippocampusNeuroprotectionOxidative PhosphorylationBrain Ischemia030218 nuclear medicine & medical imagingGlibenclamide03 medical and health sciencesAdenosine Triphosphate0302 clinical medicineSlice preparationIn vivoGlyburidemedicineAnimalsEnzyme InhibitorsRats WistarHypoxia BraineducationNeuronseducation.field_of_studyAntagonistHypoxia (medical)NADNitro Compoundsmedicine.diseaseCell HypoxiaRatsSuccinate DehydrogenaseNeuroprotective AgentsNeurologyAnesthesiaNeurology (clinical)Propionatesmedicine.symptomReactive Oxygen SpeciesCardiology and Cardiovascular Medicine030217 neurology & neurosurgerymedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct

Neuroprotection of lipoic acid treatment promotes angiogenesis and reduces the glial scar formation after brain injury

2012

After trauma brain injury, a large number of cells die, releasing neurotoxic chemicals into the extracellular medium, decreasing cellular glutathione levels and increasing reactive oxygen species that affect cell survival and provoke an enlargement of the initial lesion. Alpha-lipoic acid is a potent antioxidant commonly used as a treatment of many degenerative diseases such as multiple sclerosis or diabetic neuropathy. Herein, the antioxidant effects of lipoic acid treatment after brain cryo-injury in rat have been studied, as well as cell survival, proliferation in the injured area, gliogenesis and angiogenesis. Thus, it is shown that newborn cells, mostly corresponded with blood vessels …

MaleProgrammed cell deathAngiogenesisBlotting WesternNeovascularization PhysiologicPharmacologyBiologyNeuroprotectionAntioxidantsGlial scarNeovascularizationLesionCicatrixchemistry.chemical_compoundMicroscopy Electron TransmissionIn Situ Nick-End LabelingmedicineAnimalsRats WistarChromatography High Pressure LiquidGliogenesisThioctic AcidGeneral NeuroscienceImmunohistochemistryRatsLipoic acidNeuroprotective AgentschemistryBrain Injuriesmedicine.symptomNeurogliaNeuroscienceNeuroscience
researchProduct

Neuroprotective effects of antibodies on retinal ganglion cells in an adolescent retina organ culture

2016

Glaucoma, a neurodegenerative disease, is characterized by a progressive loss of retinal ganglion cells (rgc). Up- and down-regulated autoantibody immunoreactivities in glaucoma patients have been demonstrated. Previous studies showed protective effects of down-regulated antibodies [gamma (γ)-synuclein and glial fibrillary acidic protein [GFAP]) on neuroretinal cells. The aim of this study was to test these protective antibody effects on rgc in an organ culture model and to get a better understanding of cell-cell interactions of the retina in the context of the protective effect. We used an adolescent retinal organ culture (pig) with an incubation time of up to 4 days. Retinal explants were…

MaleRetinal Ganglion Cells0301 basic medicinePathologymedicine.medical_specialtyAdolescentgenetic structuresSwineNerve Tissue ProteinsContext (language use)Organ cultureBiochemistryRetinal ganglionAntibodies03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundOrgan Culture TechniquesGlutamate-Ammonia LigaseGlutamine synthetaseGlial Fibrillary Acidic ProteinmedicineAnimalsHumansRetinaGlial fibrillary acidic proteinbiologyMyoglobinGlaucomaRetinalEndoplasmic Reticulum StressImmunohistochemistryMolecular biologyeye diseasesNeuroprotective Agents030104 developmental biologymedicine.anatomical_structurechemistryalpha-Synucleinbiology.proteinImmunohistochemistryFemalesense organsJournal of Neurochemistry
researchProduct

Neuroprotection by erythropoietin administration after experimental traumatic brain injury.

2007

A large body of evidence indicates that the hormone erythropoietin (EPO) exerts beneficial effects in the central nervous system (CNS). To date, EPO's effect has been assessed in several experimental models of brain and spinal cord injury. This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI. Experimental TBI was induced in rats by a cryogenic injury model. rHuEPO or placebo was injected intraperitoneally immediately after the injury and then every 8 h until 2 or 14 days. Forty-eight hours after injury brain water content, an indicator of brain edema, was measured with the wet-dry method and bl…

MaleTime FactorsBrain EdemaFunctional LateralityRats Sprague-Dawleychemistry.chemical_compoundTraumatic brain injuryMedicineAnalysis of Variance Animals Blood-Brain Barrier; drug effects Brain Edema; drug therapy/etiology Brain Infarction; drug therapy/etiology Brain Injuries; complications/drug therapy Disease Models; Animal Erythropoietin; administration /&/ dosage Evans Blue; diagnostic use Functional Laterality Humans Male Neurologic Examination Neuroprotective Agents; administration /&/ dosage Rats Rats; Sprague-Dawley Reaction Time; drug effects Recombinant Proteins Time Factorsadministration /&/ dosageSpinal cord injuryEvans BlueNeurologic ExaminationGeneral Neuroscienceexperimental models of brain and spinal cord injuryExtravasationNeuroprotectionRecombinant Proteinsmedicine.anatomical_structureNeuroprotective AgentsBlood-Brain BarrierAnesthesiadiagnostic usemedicine.drugEvans BlueBrain InfarctionTraumatic brain injuryCentral nervous systemrecombinant human EPO (rHuEPO)PlaceboNeuroprotectionReaction TimeAnimalsHumansMolecular BiologyErythropoietinAnalysis of VarianceNeuroscience (all)business.industryAnimaldrug therapy/etiologymedicine.diseaseRatsDisease Models AnimalchemistryErythropoietindrug effectsBrain InjuriesDisease Modelsrecombinant human EPO (rHuEPO); experimental models of brain and spinal cord injury; NeuroprotectionNeurology (clinical)Sprague-Dawleybusinesscomplications/drug therapyDevelopmental BiologyBrain research
researchProduct

Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury. Laboratory investigation.

2007

Object The objectives of this study were to examine whether the systemic administration of recombinant human erythropoietin (rHuEPO) and its long-lasting derivative darbepoetin alfa expedited functional recovery in a rat model of sciatic nerve injury, and to compare the effects of these agents in the model. Methods Thirty male Sprague–Dawley rats received a crush injury to the left sciatic nerve and subsequently underwent either placebo treatment, daily injections of rHuEPO, or weekly injections of darbepoetin alfa. Results Both rHuEPO and darbepoetin alfa were effective in reducing neurological impairment and improving compound muscle action potentials following nerve injury. Darbepoetin …

MaleTime FactorsDarbepoetin alfaNerve CrushAction PotentialsPlaceboDrug Administration ScheduleRats Sprague-Dawleyadministration /&/ dosage/pharmacologymedicineAnimalsHumansDarbepoetin alfaMuscle SkeletalErythropoietinERYTHROPOIETINdrug effects/injuries/physiopathologySettore MED/27 - Neurochirurgiabusiness.industryAction Potentials; drug effects Animals Drug Administration Schedule Erythropoietin; administration /&/ dosage/analogs /&/ derivatives/pharmacology Humans Male Muscle; Skeletal; physiopathology Nerve Crush Neuroprotective Agents; administration /&/ dosage/pharmacology Rats Rats; Sprague-Dawley Recombinant Proteins Recovery of Function; drug effects Sciatic Nerve; drug effects/injuries/physiopathology Time FactorsGeneral MedicineSkeletalRecovery of FunctionNerve injurySciatic nerve injurymedicine.diseaseadministration /&/ dosage/analogs /&/ derivatives/pharmacologySciatic NerveNeuroprotectionRecombinant ProteinsRatsNeuroprotective AgentsNeurologyErythropoietinPeripheral nerve injuryAnesthesiadrug effectsPeripheral nerve injuryCrush injuryMuscleSurgeryNeurology (clinical)Sciatic nerveSprague-Dawleymedicine.symptomphysiopathologybusinessmedicine.drug
researchProduct

Cranioplasty with autologous bone flaps cryopreserved with Dimethylsulphoxide : does tissue processing matter

2021

Este artículo se encuentra disponible en la siguiente URL: https://www.sciencedirect.com/science/article/abs/pii/S1878875021001625?via%3Dihub En este artículo de investigación también participan: Dolores Ocete, Lucas Aranda, Ana Melero, Antonio J. Guillot, Nuria Yagüe y Carlos Botella. Este es el pre-print del siguiente artículo: Mirabet, V., García, D., Roca, A., Quiroz, A. R., Antón, J., Rodríguez-Cadarso, M., Ocete, D., Aranda, L., Melero, A., Guillot, A. J., Yagüe, N., Guillén, I. & Botella, C. (2021). Cranioplasty with autologous bone flaps cryopreserved with Dimethylsulphoxide: does tissue processing matter. World Neurosurgery, vol. 149 (may.), pp. e582?e591, que se ha publicado de fo…

MaleTime Factorsmedicine.medical_treatmentBrain EdemaSurgical Flaps0302 clinical medicineCryoprotective AgentsPostoperative ComplicationsHuesos - Crioconservación.Brain Injuries TraumaticAutograftsAutologous bone flapMiddle AgedCranioplastyResorptionAnti-Bacterial AgentsStrokeCryopreservacion of organs tissues etc.030220 oncology & carcinogenesisTissue bankVancomycinDecompressive craniectomyFemalemedicine.drugCrioconservación de órganos tejidos etc.Adultmedicine.medical_specialtyDecompressive CraniectomyAdolescentDecompressive craniectomyCráneo - Cirugía.CranioplastySkull - Surgery.03 medical and health sciencesYoung AdultmedicineHumansSurgical Wound InfectionDimethyl SulfoxideBones - Cryopreservacion.Bone ResorptionCryopreservationbusiness.industryBone storageSkullPostoperative complicationBone processingPlastic Surgery Proceduresmedicine.diseaseSurgeryHydrocephalusSurgeryNeurology (clinical)businessComplication030217 neurology & neurosurgery
researchProduct

2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1α response after traumatic brain injury in mice

2014

HIF-1α is pivotal for cellular homeostasis in response to cerebral ischemia. Pharmacological inhibition of HIF-1α may reduce secondary brain damage by targeting post-translational mechanisms associated with its proteasomal degradation and nuclear translocation. This study examined the neuroprotective effects of 2-methoxyestradiol (2ME2), the involved HIF-1α-dependent response, and alternative splicing in exon 14 of HIF-1α (HIF-1α∆Ex14) after traumatic brain injury (TBI) in mice. Intraperitoneal 2ME2 administration 30 min after TBI caused a dose-dependent reduction in secondary brain damage after 24 h. 2ME2 was physiologically tolerated, showed no effects on immune cell brain migration, and …

MaleTraumatic brain injuryBlotting WesternIschemiaCellular homeostasisBrain damagePharmacologyBiologyBiochemistryNeuroprotectionBrain IschemiaMitochondrial ProteinsMiceCellular and Molecular Neurosciencechemistry.chemical_compoundPlasminogen Activator Inhibitor 1medicineAnimalsCell NucleusNeuronsEstradiolTumor Necrosis Factor-alphaAlternative splicingMembrane ProteinsExonsHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseImmunohistochemistryUp-RegulationMice Inbred C57BLAlternative SplicingProtein TransportNeuroprotective AgentsGene Expression RegulationchemistryBrain InjuriesPlasminogen activator inhibitor-1Tumor necrosis factor alphamedicine.symptomNeuroscienceInjections IntraperitonealSubcellular FractionsJournal of Neurochemistry
researchProduct

Results from an international case-control study of childhood brain tumors: The role of prenatal vitamin supplementation

1998

An international case-control study of primary pediatric brain tumors included interviews with mothers of cases diagnosed from 1976 to 1994 and mothers of population controls. Data are available on maternal vitamin use during pregnancy for 1051 cases and 1919 controls from eight geographic areas in North America, Europe, and Israel. Although risk estimates varied by study center, combined results suggest that maternal supplementation for two trimesters may decrease risk of brain tumor (odds ratio [OR] 0.7, 95% confidence interval [CI] 0.5-0.9), with a trend of less risk with longer duration of use (p trend = 0.0007). The greatest risk reduction was among children diagnosed under 5 years of …

MaleVitaminPediatricsmedicine.medical_specialtyAdolescentInternational CooperationHealth Toxicology and MutagenesisPopulationPrenatal careProtective Agentschemistry.chemical_compoundPregnancyConfidence IntervalsOdds RatioHumansMedicineChildeducationPrenatal vitaminsLikelihood Functionseducation.field_of_studyPregnancyDose-Response Relationship DrugBrain Neoplasmsbusiness.industryPublic Health Environmental and Occupational HealthPrenatal CareVitaminsmedicine.diseaseMicronutrientchemistryCase-Control StudiesChild PreschoolDietary SupplementsFemalebusinessMultivitaminBreast feedingResearch Article
researchProduct

Xenon Improves Neurologic Outcome and Reduces Secondary Injury Following Trauma in an In Vivo Model of Traumatic Brain Injury*

2014

Objectives: To determine the neuroprotective efficacy of the inert gas xenon following traumatic brain injury and to determine whether application of xenon has a clinically relevant therapeutic time window. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male C57BL/6N mice (n = 196). Interventions: Seventy-five percent xenon, 50% xenon, or 30% xenon, with 25% oxygen (balance nitrogen) treatment following mechanical brain lesion by controlled cortical impact. Measurements and Main Results: Outcome following trauma was measured using 1) functional neurologic outcome score, 2) histological measurement of contusion volume, and 3) analysis of locomotor functio…

MaleXenonINTRACRANIAL-PRESSURE1110 NursingCritical Care and Intensive Care MedicineGAIT ABNORMALITIESXenonGaitIntracranial pressureintegumentary systemBrainGLYCINE SITEINTRACEREBRAL-HEMORRHAGED-ASPARTATE RECEPTORNeuroprotective AgentsTreatment OutcomeAnesthesiahead traumaneuroprotectionLife Sciences & BiomedicinePOTASSIUM CHANNELSLocomotioncirculatory and respiratory physiologyinorganic chemicalsTraumatic brain injurychemistry.chemical_elementNeuroprotection1117 Public Health and Health ServicesHead traumaCritical Care MedicineIn vivoGeneral & Internal MedicineAdministration InhalationmedicineAnimalscardiovascular diseasesIntracerebral hemorrhageScience & Technologybusiness.industry1103 Clinical Sciencesbrain injurymedicine.diseaseCONTROLLED CORTICAL IMPACTCOMPETITIVE-INHIBITIONEmergency & Critical Care MedicineMice Inbred C57BLDisease Models AnimalCOGNITIVE DEFICITSchemistryBrain InjuriesClosed head injurybusinessCLOSED-HEAD INJURYinert gasesCritical Care Medicine
researchProduct

Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury …

2019

Background.Xenon is a noble gas with neuroprotective properties. We previously showed that xenon improves short and long-term outcomes in young adult mice after controlled cortical impact (CCI). This is a follow-up study investigating xenon’s effect on very long-term outcome and survival. Methods.C57BL/6N (n=72) young adult male mice received single CCI or sham surgery and were treated with either xenon (75%Xe:25%O2) or control gas (75% N2:25%O2). The outcomes used were: 1) 24-hour lesion volume and neurological outcome score; 2)contextual fear-conditioning at 2 weeks and 20 months; 3) corpus callosum white matter quantification; 4) immunohistological assessment of neuroinflammation and neu…

MaleXenonhippocampusnerve degenerationCorpus callosumBUPRENORPHINEneuroinflammationMice0302 clinical medicineCognition030202 anesthesiologyAnesthesiologyBrain Injuries TraumaticMedicineEPIDEMIOLOGYYoung adultmemory disordersNeuronstraumatic brain injurySham surgeryBrain3. Good healthD-ASPARTATE RECEPTORmedicine.anatomical_structureNeuroprotective AgentsAnesthesianeuroprotectionmedicine.symptomLife Sciences & BiomedicineTraumatic brain injuryHYPOPITUITARISMNeuroprotectionWhite matter03 medical and health sciencesANALGESIAINHALED XENONAnimalsgeneral anaesthesiaSurvival analysisHYPOTHERMIAInflammationScience & Technologybusiness.industry1103 Clinical SciencesHypothermiamedicine.diseaseCOMPETITIVE-INHIBITIONSurvival AnalysisMice Inbred C57BLPATHOLOGYDisease Models AnimalAnesthesiology and Pain MedicineChronic DiseasebusinessCognition Disorders030217 neurology & neurosurgeryWHITE-MATTER DAMAGEFollow-Up StudiesBritish journal of anaesthesia
researchProduct